Biologic therapies for inflammatory eye disease

被引：79

作者：

Lim, Lyndell ^{[1
]}

Suhler, Eric B. ^{[1
]}

Smith, Justine R. ^{[1
]}

机构：

[1] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA

来源：

CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY | 2006年 / 34卷 / 04期

关键词：

biologic; immunosuppression; uveitis;

D O I：

10.1111/j.1442-9071.2006.01225.x

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

The era of biologic medical therapies provides new options for patients with treatment-resistant inflammatory eye disease. In this review, the authors summarize current published experience in a rapidly progressing clinical field, including the use of biologics, such as the tumour necrosis factor blockers, daclizumab and rituximab, and related agents, interferons and intravenous immunoglobulin, for the treatment of uveitis, scleritis and orbital inflammation. Reports of dramatic recoveries in patients with recalcitrant ocular inflammation who have received such therapies must be balanced against the high cost of biologics and the potential for serious, and at times unanticipated, complications of this treatment.

引用

收藏

页码：365 / 374

页数：10

相关论文

共 111 条

[1]

Adams AB, 2005, J RHEUMATOL, V32, P1374

[2] Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab [J].

Ahmadi-Simab, K ;

Lamprecht, P ;

Nölle, B ;

Ai, M ;

Gross, WL .

ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (07) :1087-1088

[3] Interferon alfa-2a in the treatment of Behcet disease - A randomized placebo-controlled and double-blind study [J].

Alpsoy, E ;

Durusoy, C ;

Yilmaz, E ;

Ozgurel, Y ;

Ermis, O ;

Yazar, S ;

Basaran, E .

ARCHIVES OF DERMATOLOGY, 2002, 138 (04) :467-471

[4]

Baughman RP, 2005, CHEST, V128, P1062, DOI 10.1378/chest.128.2.1062

[5] Progressive multifocal leukoencephalopathy and natalizumab - Unforeseen consequences [J].

Berger, JR ;

Koralnik, IJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (04) :414-416

[6] Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β [J].

Bielekova, B ;

Richert, N ;

Howard, T ;

Blevins, G ;

Markovic-Plese, S ;

McCartin, J ;

Würfel, J ;

Ohayon, J ;

Waidmann, TA ;

McFarland, HF ;

Martin, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (23) :8705-8708

[7] Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept [J].

Braun, J ;

Baraliakos, X ;

Listing, J ;

Sieper, J .

ARTHRITIS AND RHEUMATISM, 2005, 52 (08) :2447-2451

[8] Successful treatment of Wegener's granulomatosis associated scleritis with rituximab [J].

Cheung, CMG ;

Murray, PI ;

Savage, COS .

BRITISH JOURNAL OF OPHTHALMOLOGY, 2005, 89 (11) :1542-1542

[9] Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis - A randomized, double-blind, placebo-controlled, dose-escalation trial [J].

Choy, EHS ;

Isenberg, DA ;

Garrood, T ;

Farrow, S ;

Ioannou, Y ;

Bird, H ;

Cheung, N ;

Williams, B ;

Hazleman, B ;

Price, R ;

Yoshizaki, K ;

Nishimoto, N ;

Kishimoto, T ;

Panayi, GS .

ARTHRITIS AND RHEUMATISM, 2002, 46 (12) :3143-3150

[10] Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure -: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial [J].

Chung, ES ;

Packer, M ;

Lo, KH ;

Fasanmade, AA ;

Willerson, JT .

CIRCULATION, 2003, 107 (25) :3133-3140

← 1 2 3 4 5 6 7 8 9 10 →